Are you Dr. Argani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 66 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans Street
Baltimore, MD 21287
Summary
- Dr. Pedram Argani, MD is a board certified pathologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland and Pennsylvania. He is affiliated with Johns Hopkins Hospital and is a Professor of Pathology at Johns Hopkins University School of Medicine; Director and principal consultant.
Education & Training
Memorial Sloan Kettering Cancer Center Oncologic PathologyFellowship, Selective Pathology, 1995 - 1996
University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 1993 - 1995
Perelman School of Medicine at the University of PennsylvaniaClass of 1992
Certifications & Licensure
MD State Medical License 1997 - 2026
PA State Medical License 1993 - 1996- American Board of Pathology Anatomic Pathology
Awards, Honors, & Recognition
- Top Doctors:Baltimore Area Castle Connolly, 2012
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Pre-Operative Radiation and Veliparib for Breast Cancer Start of enrollment: 2013 Jul 22
Publications & Presentations
PubMed
- Clear Cell Adenocarcinoma of the Urinary Tract Primary to the Renal Pelvis: A Multi-institutional Clinicopathologic and Molecular Study of Five Patients.Shreeya Indulkar, Efrain Ribeiro, Adeboye O Osunkoya, Carlos N Prieto-Granada, Giovanna A Giannico
The American Journal of Surgical Pathology. 2025-01-01 - Diagnostic and Prognostic/Therapeutic Significance of Comprehensive Analysis of Bone and Soft Tissue Tumors Using Optical Genome Mapping and Next-generation Sequencing.Jen Ghabrial, Victoria Stinnett, Efrain Ribeiro, Melanie Klausner, Laura Morsberger
Modern Pathology. 2024-12-13 - Genetic validation of a TSC2 immunohistochemistry assay in TSC/mTOR-pathway altered renal tumors.Amir Akbari, Clarence Rachel Villanueva, Ondrej Hes, Sean R Williamson, Shivani Kandukuri
Human Pathology. 2024-11-19
Press Mentions
Value of ER/PR Tests on DCIS Core Biopsies QuestionedOctober 18th, 2016
Needle Biopsies for Noninvasive Breast Cancer: Routine Analysis Wastes MillionsAugust 9th, 2016
Genitourinary Tumor Pathology: Introductory CommentsDecember 7th, 2011
